The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer
Author:
Affiliation:
1. Department of Hematology and Medical Oncology; Winship Cancer Institute; Emory University; Atlanta Georgia
2. Editor-in-Chief, Cancer
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.29139/fullpdf
Reference31 articles.
1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004
2. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004
3. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS);Fukuoka;J Clin Oncol,2011
4. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib;Pao;Proc Natl Acad Sci U S A,2004
5. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005
Cited by 63 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. EGFR/HER Family Inhibitors;Molecules Engineered Against Oncogenic Proteins and Cancer;2023-09-08
2. ReMODE: a deep learning-based web server for target-specific drug design;Journal of Cheminformatics;2022-12-12
3. Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFRdel19/T790M/C797S and EGFRL858R/T790M/C797S);Bioorganic & Medicinal Chemistry Letters;2022-09
4. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer;Annals of Oncology;2022-05
5. Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness;Cancer Letters;2022-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3